Literature DB >> 14724559

Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine--Colorado, December 2003.

.   

Abstract

Influenza activity started earlier than usual in the United States this season, with widespread influenza activity reported in 10 states by November 22, 2003. The predominant influenza viruses (A/Fujian/411/2002 [H3N2]-like viruses) circulating this season differ antigenically from the 2003-04 influenza A (H3N2) vaccine strain. A retrospective cohort study was conducted among workers at a Colorado hospital to provide preliminary data on the effectiveness of trivalent inactivated influenza vaccine (TIV) against influenza-like illness (ILI). This report summarizes the results of that study, which indicated that TIV had no or low effectiveness against ILI. However, additional studies are needed to evaluate the effectiveness of the 2003-04 vaccine against laboratory-confirmed influenza and influenza-related complications, including hospitalization and death. Influenza vaccine continues to be recommended, particularly for persons at increased risk for influenza-related complications, their household contacts, and health-care personnel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724559

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  23 in total

1.  Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation.

Authors:  Xiangjun Du; Libo Dong; Yu Lan; Yousong Peng; Aiping Wu; Ye Zhang; Weijuan Huang; Dayan Wang; Min Wang; Yuanji Guo; Yuelong Shu; Taijiao Jiang
Journal:  Nat Commun       Date:  2012-02-28       Impact factor: 14.919

2.  Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Federica Banfi; Paolo Durando; Laura Sticchi; Giancarlo Icardi; Roberto Gasparini
Journal:  Clin Vaccine Immunol       Date:  2006-01

3.  Influenza - Expect the unexpected.

Authors:  John M Conly; B Lynn Johnston
Journal:  Can J Infect Dis       Date:  2004-01

Review 4.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

5.  Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.

Authors:  Anwar M Hashem; Anathea S Flaman; Aaron Farnsworth; Earl G Brown; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

6.  Signs of the 2009 influenza pandemic in the New York-Presbyterian Hospital electronic health records.

Authors:  Hossein Khiabanian; Antony B Holmes; Brendan J Kelly; Mrinalini Gururaj; George Hripcsak; Raul Rabadan
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

7.  Low-dimensional clustering detects incipient dominant influenza strain clusters.

Authors:  Jiankui He; Michael W Deem
Journal:  Protein Eng Des Sel       Date:  2010-10-29       Impact factor: 1.650

8.  Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

Authors:  V Baldo; T Baldovin; A Floreani; E Fragapane; R Trivello
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.317

Review 9.  The role of genomics in tracking the evolution of influenza A virus.

Authors:  Alice Carolyn McHardy; Ben Adams
Journal:  PLoS Pathog       Date:  2009-10-26       Impact factor: 6.823

10.  Influenza vaccine effectiveness among US military basic trainees, 2005-06 season.

Authors:  Jennifer K Strickler; Anthony W Hawksworth; Christopher Myers; Marina Irvine; Margaret A K Ryan; Kevin L Russell
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.